Content
08/21/2024 New York, NY USA
PreciseDx completed $20.7 million Series B Round funding. Investors include Eventide Asset Management (lead), GenHenn Capital.
#AI  #MedTech  #Life Science  
About
PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
Startup
PreciseDx
https://precisedx.ai Claim Profile
Location:
New York, NY USA
Sector:
AI
MedTech
Life Science
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.